Search Result
Results for "
STING Agonist
" in MedChemExpress (MCE) Product Catalog:
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-143320
-
|
|
STING
|
Cancer
|
|
STING agonist-17 (compound 4a) is a potent STING agonist with an IC50 value of 0.062 nM. STING agonist-17 has anti-cancer activity for tumor immunization .
|
-
-
- HY-143896
-
|
|
STING
|
Cancer
|
|
STING agonist-7 is a non-nucleotide STING agonist. STING agonist-7 binds selectively to mouse STING but not human STING. STING agonist-7 penetrates cell membrane poorly .
|
-
-
- HY-103665
-
|
|
STING
|
Cancer
|
|
STING agonist-3, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pIC50 of 7.5 and 9.5, respectively. STING agonist-3 has durable anti-tumor effect and tremendous potential to improve treatment of cancer .
|
-
-
- HY-122568
-
|
|
STING
|
Cancer
|
|
STING agonist-15 (Compound STING agonist-C11) Is a STING agonist. STING agonist-15 can be used for research of cancer and immune response .
|
-
-
- HY-149781
-
|
|
STING
|
Cancer
|
|
STING agonist-34 (Compound 12L) is a potent STING agonist with an IC50 value of 1.15 μM and an EC50 of 0.38 μM in THP1 cells. STING agonist-34 could be used in cancer research .
|
-
-
- HY-153546
-
|
|
STING
|
Cancer
|
|
STING agonist-31 is a STING agonist, with EC50 values of 0.24 and 39.51 μM for h-STING and m-STING. STING agonist-31 has antitumor efficiency .
|
-
-
- HY-147834
-
|
|
STING
|
Cancer
|
|
STING agonist-9 (Compound 45) is a potent STING agonist with an EC50 of 1.2 nM and 32.82 μM against h-STING and m-STING, respectively. STING agonist-9 shows antitumor activity .
|
-
-
- HY-139179
-
|
|
STING
|
Infection
Cancer
|
|
STING agonist-14 (compound 12b) is a potent STING agonist that is efficacious across species. STING agonist-14 could activate the pathway by directly binding human STING. STING agonist-14 can be used for the research of tumours or viral infections .
|
-
-
- HY-175714
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
STING agonist-46 is an orally active STING agonist. STING agonist-46 activates the STING signaling pathway, promoting phosphorylation of TBK1 and IRF3, and secretion of IFN-β and IP-10. STING agonist-46 directly binds to STING and increases its thermal stability. STING agonist-46 demonstrates potent anti-tumor efficacy in B16F10, CT26, and 4T1 mouse models. STING agonist-46 can be used for cancer immunotherapy studies .
|
-
-
- HY-152962
-
|
|
STING
|
Infection
|
|
STING agonist-29 (CF511) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, exhibits activity against SARS-CoV series strains .
|
-
-
- HY-152960
-
|
|
STING
|
Infection
|
|
STING agonist-27 (CF509) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, exhibits activity against SARS-CoV series strains .
|
-
-
- HY-143321
-
|
|
STING
|
Cancer
|
|
STING agonist-13 is a stimulator of interferon genes (STING) agonist, for cancer immunity via STING-mediated immune activation. STING agonist-13 can stimulate STING downstream signaling and promoting type I interferon immune responses. STING agonist-13 significantly decreases tumor volume and shows immunological memory-derived cancer inhibition .
|
-
-
- HY-148546
-
|
|
STING
|
Cancer
|
|
STING agonist-21 (compound 1) is a STING agonist, with an EC50 of 592.8 nM. STING agonist-21 can be used for cancer research .
|
-
-
- HY-152961
-
|
|
STING
|
Infection
|
|
STING agonist-28 (CF510) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
|
-
-
- HY-152957
-
|
|
STING
|
Infection
|
|
STING agonist-24 (CF504) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
|
-
-
- HY-152959
-
|
|
STING
|
Infection
Cancer
|
|
STING agonist-26 (CF508) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
|
-
-
- HY-152956
-
|
|
STING
|
Infection
Cancer
|
|
STING agonist-23 (CF502) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
|
-
-
- HY-152958
-
|
|
STING
|
Infection
|
|
STING agonist-25 (CF505) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
|
-
-
- HY-178338
-
|
|
STING
|
Cancer
|
|
STING agonist-47 is a STING agonist with an EC50 of 0.72 μM and a Kd of 176 nM. STING agonist-47 is a dimer of MSA-2 (HY-136927). STING agonist-47 can be used for the research of cancer, such as breast cancer .
|
-
-
- HY-149267
-
|
|
STING
SARS-CoV
|
Infection
|
|
STING agonist-30 is a potent STING agonist. STING agonist-30 exhibits STING-dependent immune activation. STING agonist-30 has extensive inhibitory effects on various viruses, including the herpes simplex virus (HSV), rotavirus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
|
-
-
- HY-172671
-
|
|
STING
|
Cancer
|
|
STING agonist-43 (Compound 67) is a selective STING agonist (EC50: 20.53 μM). STING agonist-43 selectively amplifies cGAMP-dependent STING pathway activation by modulating STING oligomerization. B16.F10 has antitumor activity in a mouse melanoma model. STING agonist-43 can be used for the study of cancer immunity .
|
-
-
- HY-176126
-
|
|
STING
|
Inflammation/Immunology
|
|
STING agonist-42 (compound 8a) is a potent STING agonist. STING agonist-42 activates STING in THP1 and RAW 264.7 cells with EC50s of 0.06 and 14.15 μM, respectively .
|
-
-
- HY-131994
-
|
|
STING
|
Infection
Cancer
|
STING agonist-16 (1a) is a specific stimulator of interferon genes (STING) agonist. STING agonist-16 (1a) can be used as a potential antiviral and antitumor tool .
|
-
-
- HY-177338
-
|
|
STING
Cyclic GMP-AMP Synthase
IFNAR
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
STING agonist-45 is a selective STING agonist (EC50 = 0.28 μM). STING agonist-45 activates the innate immune response through the cGAS-STING pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust STING activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8 + T cell infiltration in mouse models. STING agonist-45 is promising for the study of STING-related diseases .
|
-
-
- HY-152955
-
|
|
STING
|
Infection
Inflammation/Immunology
|
|
STING agonist-22 (CF501) is a potent non-nucleotide STING agonist. STING agonist-22 is a adjuvant by activating STING to induce the type I interferon (IFN-I) response and proinflammatory cytokine production. STING agonist-22 can be used as an adjuvant to boost the original protein vaccine, producing potent, broad, and long-term immune protection. STING agonist-22 can be used for SARS-CoV-2 variants and sarbecovirus diseases research .
|
-
-
- HY-158711
-
|
|
STING
|
Cancer
|
|
STING agonist-38 (compound 58) is a potent agonist of STING, with the EC50 of 0.05 μM in THP1 cells. STING agonist-38 has certain oral bioactivity .
|
-
-
- HY-123943
-
|
|
STING
|
Cancer
|
|
STING agonist-4 is an stimulator of Interferon Genes (STING) receptor agonist with an apparent inhibitory constant (IC50) of 20 nM. STING agonist-4 is a two symmetry-related amidobenzimidazole (ABZI)-based compound to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function .
|
-
-
- HY-176257
-
|
|
STING
|
Cancer
|
|
STING agonist-44 (Compound 4) is a potent and selective STING agonist with an EC50 value of 5.68 for IRF induction in THP1 cells and 2.212 μM in RAW cells. STING agonist-44 activates the STING pathway, inducing the production of type I interferons and pro-inflammatory cytokines (e.g., CXCL10, TNFα). STING agonist-44 is promising for research of cancers .
|
-
-
- HY-148068
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
STING agonist-20 (compound 95) is a potent STING agonist used in the synthesis of XMT-2056. STING agonist-20 can be used as a vaccine adjuvant in the study of cancer and other inflammatory, immune diseases .
|
-
-
- HY-144329
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
STING agonist-11 (Compound 92) is a potent small molecule cyclic urea activator of STING with EC50 of 18 nM. Activation of STING is a highly promising approach in immunotherapy .
|
-
-
- HY-144328
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
STING agonist-10 (Compound 91) is a potent small molecule cyclic urea activator of STING with the EC50 of 2600 nM. Activation of STING is a highly promising approach in immunotherapy .
|
-
-
- HY-147010
-
-
-
- HY-150074
-
|
|
STING
ADC Payload
|
Cancer
|
|
STING agonist-18 (compound 1a) is a STING agonist that can be used for synthesis of antibody-drug conjugates (ADCs), such Trastuzumab (HY-P9907) conjugate .
|
-
-
- HY-103665A
-
|
|
STING
|
Cancer
|
|
STING agonist-3 trihydrochloride, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pEC50 of 7.5 and 9.5, respectively. STING agonist-3 trihydrochloride has durable anti-tumor effect and tremendous potential to improve treatment of cancer .
|
-
-
- HY-153987
-
|
|
STING
|
Cancer
|
|
STING agonist-33 (example 1) is an agonist of STING (stimulator of interferon genes) based on 4-ethyl-2-methylthiazole-5-carboxylic acid [1] .
|
-
-
- HY-144168A
-
|
|
STING
|
Inflammation/Immunology
|
|
STING agonist-8 dihydrochloride (compound 5-AB) is a potent STING agonist with an EC50 of 27 nM in THP1-Dual KI-hSTING-R232 cells .
|
-
-
- HY-144168
-
|
|
STING
|
Inflammation/Immunology
|
|
STING agonist-8 is a potent STING agonist with an EC50 of 27 nM in THP1-Dual KI-hSTING-R232 cells (WO2021239068A1, compound 5-AB) .
|
-
-
- HY-150074A
-
|
|
STING
ADC Payload
|
Cancer
|
|
STING agonist-18 (compound 1a) diTFA is a STING agonist that can be used for synthesis of antibody-drug conjugates (ADCs), such Trastuzumab (HY-P9907) conjugate .
|
-
-
- HY-150075
-
|
|
STING
|
Others
|
|
STING agonist-19 can be used to synthesize ISAC (immune-stimulating antibody conjugates) molecule.
|
-
-
- HY-19711
-
|
G10
|
STING
Virus Protease
|
Infection
|
|
STING agonist-1 (G10) is human-specific STING agonist that elicits antiviral activity against emerging Alphaviruses. G10 potently blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) with IC90 of 24.57 μM .
|
-
-
- HY-148346
-
|
|
Drug-Linker Conjugates for ADC
STING
|
Cancer
|
|
STING agonist-20-Ala-amide-PEG2-C2-NH2 is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used for the research of cancer .
|
-
-
- HY-148346A
-
|
|
Drug-Linker Conjugates for ADC
STING
|
Cancer
|
|
STING agonist-20-Ala-amide-PEG2-C2-NH2 (Compound 30b) TFA is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used for the research of cancer .
|
-
-
- HY-112921A
-
|
|
STING
|
Inflammation/Immunology
|
|
diABZI STING agonist-1 is a tautomerism of diABZI STING agonist-1 tautomerism (HY-112921). diABZI STING agonist-1 is a selective stimulator of interferon genes (STING) receptor agonist, with EC50s of 130, 186 nM for human and mouse, respectively .
|
-
-
- HY-112921
-
|
|
STING
|
Inflammation/Immunology
|
|
diABZI STING agonist-1 tautomerism is a tautomerism of diABZI STING agonist-1 (HY-112921A). diABZI STING agonist-1 tautomerism is a selective stimulator of interferon genes (STING) receptor agonist, with EC50s of 130, 186 nM for human and mouse, respectively .
|
-
-
- HY-112921B
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
diABZI STING agonist-1 (trihydrochloride) is a selective stimulator of interferon genes (STING) receptor agonist, with EC50s of 130, 186 nM for human and mouse, respectively.
|
-
-
- HY-176809
-
|
|
STING
|
Cancer
|
|
Parent CDN is a cyclic dinucleotide and a STING agonist. Parent CDN exhibits anti-tumor activity .
|
-
-
- HY-139586B
-
|
MK-1454 (isomer 2)
|
STING
|
Cancer
|
|
Ulevostinag isomer 2 (MK-1454 isomer 2) is the isomer of Ulevostinag. Ulevostinag is a STING agonist .
|
-
-
- HY-139586D
-
|
MK-1454 (isomer 4)
|
STING
|
Cancer
|
|
Ulevostinag isomer 4 (MK-1454 isomer 4) is the isomer of Ulevostinag. Ulevostinag is a STING agonist .
|
-
-
- HY-160406
-
|
|
STING
IFNAR
|
Cancer
|
|
SNX281 is a systemically active non-CDN STING agonist that binds to the STING protein. SNX281 promotes signal transduction of the cGAS-STING pathway, and increases cellular responses to tumor cells. SNX281 activates STING and leads to the production of type I IFNs and proinflammarory cytokines, ultimately stimulating the infilatration of immune cells into the tumor microenvironment. SNX281 enhances anti-tumor immunity, potentially overcoming resistance to checkpoint inhibitors in some cancer. SNX281 can be used in the research for anti-tumor immunity .
|
-
-
- HY-175166
-
|
|
STING
|
Inflammation/Immunology
|
|
BMS-025 is a orthosteric STING agonist. BMS-025 can induces chemical shift of STING M271 residue, further activating STING IFN signaling. BMS-025 can be used for monogenic autoinflammatory disease like SAVI disease research .
|
-
- HY-156290
-
-
- HY-162133
-
|
|
STING
|
Cancer
|
|
MSA-2-Pt is an orally active STING agonist that has good cell membrane permeability. MSA-2-Pt can induce cell death by Pt, which may release damaged DNA to activate the cGAS-STING pathway. Besides, MSA-2-Pt can activate the STING pathway directly by MSA-2. MSA-2-Pt can be used for the research of cancer .
|
-
- HY-175168
-
|
|
STING
|
Inflammation/Immunology
|
|
diABZI-a1 is a orthosteric STING agonist with EC50 of 117 nM for IFNβ in human PBMCs. diABZI-a1 can be used for monogenic autoinflammatory disease like SAVI disease research .
|
-
- HY-174170
-
|
|
STING
|
Cancer
|
|
(S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide (compound 4) is a STING agonist containing a key amide benzimidazole (ABZI) component and shows reproducible inhibition of 3H-cGAMP binding to STING with an apparent inhibition constant IC50 of 14 μM. (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide can be used for tumor research .
|
-
![(S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide](//file.medchemexpress.eu/product_pic/hy-174170.gif)
- HY-164278
-
-
- HY-173316
-
|
|
STING
|
Inflammation/Immunology
|
|
STING-IN-12 (compound Y2) is an inhibitor of STING. STING-IN-12 inhibits IFNβ gene expression (IC50=0.75μM) induced by SR717. STING-IN-12 inhibits STING pathway activation induced by the STING agonist SR717 in THP1 cells and MSA-2-induced STING pathway activation in vivo in mice .
|
-
- HY-162465
-
|
|
STING
|
Infection
Inflammation/Immunology
Cancer
|
|
BDW568 is a STING agonist that can selectively activate the human STING A230 allele. BDW568 can be used to activate STING A230-engineered macrophages in macrophage-based immunotherapy .
|
-
- HY-128481
-
|
|
STING
|
Cancer
|
|
SB24011 is a STING-TRIM29 interaction inhibitor with a IC50 value of 3.85 μM. SB24011 enhances STING immunity by upregating STING protein levels, thereby enhancing the immunotherapy effect of STING agonists and anti-PD-1 antibodies through systemic anticancer immunity .
|
-
- HY-164919
-
-
- HY-168803
-
|
|
STING
|
Cancer
|
|
BDW-OH is an active metabolite of BDW568 (HY-162465 ). BDW568 is a STING agonist that can selectively activate the human STING A230 allele.
|
-
- HY-151264
-
|
|
STING
|
Cancer
|
|
BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 can selectively stimulate the STING pathway. BSP16 can be used for the research of cancer .
|
-
- HY-158048
-
|
|
PROTACs
STING
|
Inflammation/Immunology
|
|
UNC9036 is a PROTAC-based STING degrader, with a DC50 of 227 nM. UNC9036-mediated STING degradation is proteasome and VHL dependent (Structure Note: Red, STING agonist diABZI (HY-112921A); Blue, VHL ligand VH032 (HY-120217); Black, linker) .
|
-
- HY-130115
-
|
|
STING
|
Cancer
|
|
IACS-8803 is a highly potent cyclic dinucleotide STING agonist with robust systemic antitumor efficacy .
|
-
- HY-130116
-
|
|
STING
|
Cancer
|
|
IACS-8779 is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy .
|
-
- HY-163668
-
|
|
STING
|
Cancer
|
|
MK-2118 is a GMP-synthesized STING agonist with the potential to inhibit advanced/metastatic solid tumors or lymphomas. .
|
-
- HY-137724A
-
|
Cyclic-di-IMP disodium
|
STING
|
Cancer
|
|
C-di-IMP disodium is a STING agonist. C-di-IMP disodium can be used in tumor research .
|
-
- HY-175462
-
|
|
STING
|
Cancer
|
|
INI3069 is a selective human stimulator of interferon gene (STING) agonist. INI3069 is promising for research of cancers .
|
-
- HY-154850
-
|
|
STING
|
Cancer
|
|
F-CRI1 is a potent STING agonist with a Kd value of 40.62 nM. F-CRI1 is a radioactive probe with 18F-labeled modification. F-CRI1 can be used to study STING visualization in the tumor microenvironment .
|
-
- HY-137724
-
|
Cyclic-di-IMP
|
STING
|
Cancer
|
|
C-di-IMP (Cyclic-di-IMP) is a STING agonist. C-di-IMP can be used for the research of tumor .
|
-
- HY-137320
-
|
|
STING
|
Cancer
|
|
diABZI-C2-NH2, an active analogue containing a primary amine functionality, is a STING agonist .
|
-
- HY-176541
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
diABZI-Mal is a STING agonist. diABZI-Mal activates cGAS-STING pathway to induce cytokine production such as interferon-type I. diABZI-Mal promotes maturation of DC cells and efficiently induces CD8 + T immune reaction. diABZI-Mal inhibits tumor growth .
|
-
- HY-130116A
-
|
|
STING
|
Cancer
|
|
IACS-8779 disodium is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy. IACS-8779 disodium shows robust activation of the STING pathway in vitro and a superior systemic anti-tumor response in the B16 murine model of melanoma .
|
-
- HY-141514
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
MSA-2 dimer is a selective, orally active non-nucleotide STING agonist (Kd=145 μM) with long-term antitumor and immunogenic activity. MSA-2 dimer is bound to STING as a non-covalent dimer exhibiting higher permeability than cyclic dinucleotide .
|
-
- HY-111999A
-
|
|
STING
|
Cancer
|
|
E7766 diammonium salt is a macrocycle-bridged STING agonist with a Kd of 40 nM. E7766 diammonium salt shows potent pan-genotypic and antitumor activities .
|
-
- HY-111999B
-
|
|
STING
|
Cancer
|
|
E7766 disodium is a macrocycle-bridged STING agonist with a Kd of 40 nM. E7766 disodium shows potent pan-genotypic and antitumor activities .
|
-
- HY-155100
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
BI 7446 is a cyclic dinucleotide (CDN)-based potent and selective stimulator of interferon genes (STING) agonist. BI 7446 can activate all five STING variants in cells and induce tumor-specific immune-mediated tumor rejection. BI 7446 can be used for immuno-oncology research .
|
-
- HY-139586
-
|
MK-1454
|
STING
|
Cancer
|
|
Ulevostinag (MK-1454) is a potent cyclic dinucleotide agonist stimulator of interferon genes (STING). Ulevostinag (MK-1454) acts in the intra-tumoral route by targeting the stimulator of interferon genes (STING) protein. Ulevostinag (MK-1454) can be used for immuno-tumor cancer disease research .
|
-
- HY-148029
-
|
TAK-676
|
STING
|
Cancer
|
|
Dazostinag disodium (TAK-676) is an agonist of STING, triggering the activation of STING signaling pathway and type I interferons. Dazostinag disodium is also a modulator of immune system, resulting complete regressions and durable memory T-cell immunity. Dazostinag disodium promotes durable IFN-dependent antitumor immunity .
|
-
- HY-174308
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
ZSA-215 is a potent and orally active STING agonist with an EC50 of 3.3 μM. ZSA-215 enhances STING signaling through promoting the phosphorylation of STING and interferon regulatory factor 3 (IRF3) and secretion of IFN-β. ZSA-215 inhibits tumor regression and long-term survival of mice in MC38 colon cancer model. ZSA-215 can be used to the study of colon cancerr .
|
-
- HY-130115A
-
|
|
STING
|
Cancer
|
|
IACS-8803 disodium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 disodium has a robust systemic antitumor efficacy .
|
-
- HY-130115B
-
|
|
STING
|
Cancer
|
|
IACS-8803 diammonium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 diammonium has a robust systemic antitumor efficacy .
|
-
- HY-136927
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
MSA-2, a potent and orally available non-nucleotide STING agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models .
|
-
- HY-168034
-
|
|
STING
|
Infection
Inflammation/Immunology
|
|
diABZI-4 is an oral active STING agonist with broad-spectrum antiviral activity. diABZI-4 induces the production of pro-inflammatory cytokines and lymphocyte activation by activating STING, thereby inhibiting the replication of influenza A virus (IAV), SARS-CoV-2, and human rhinovirus (HRV), with an EC50 range of 11.8-199 nM .
|
-
- HY-10964
-
Vadimezan
Maximum Cited Publications
59 Publications Verification
DMXAA; ASA-404
|
STING
IFNAR
Influenza Virus
|
Infection
Cancer
|
|
Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
|
-
- HY-173404
-
|
|
STING
Interleukin Related
IFNAR
TNF Receptor
CXCR
|
Inflammation/Immunology
Cancer
|
|
VB-85247 is a STING agonist. VB-85247 induces upregulation of inflammatory cytokines IFNα/β, TNFα, IL6, and CXCL10, as well as maturation and activation of dendritic cells by activating the STING pathway. VB-85247 can achieve regression of intrabladder tumors and can be used in bladder cancer research .
|
-
- HY-139586C
-
|
MK-1454 (isomer 3)
|
STING
|
Cancer
|
|
Ulevostinag (isomer 3) (example 246) is a potent cyclic dinucleotide agonist stimulator of interferon genes (STING). Ulevostinag (isomer 3) plays an important role in anti-tumor research .
|
-
- HY-173399
-
|
|
STING
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
hSTING activator-1 (Compound 68) is a STING agonist. hSTING activator-1 can effectively activate multiple human STING variants (R232, H232, HAQ) with EC50 values of 56 nM, 89 nM and 51 nM, respectively. hSTING activator-1 activates the type I interferon pathway by directly binding to STING protein and stabilizing its conformation, promoting downstream IRF3 phosphorylation and cytokine release. hSTING activator-1 inhibits fibrosarcoma tumor growth and has potential in cancer research .
|
-
- HY-152861
-
|
TAK-676 free base
|
STING
|
Cancer
|
|
Dazostinag (TAK-676 free base) is an agonist of stimulator of interferon genes (STING) protein with antineoplastic activity. Dazostinag can serve as a playload to synthesis antibody-drug conjugates (ADCs) .
|
-
- HY-168887
-
|
|
STING
|
Cancer
|
|
ZSA-51 is a potent and orally active STING agonist. ZSA-51 shows anticancer activity. ZSA-51 remodeles immune microenvironment both in tumor and lymph node .
|
-
- HY-169483
-
-
- HY-159146
-
-
- HY-162874
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
diABZI-V/C-DBCO (Compound 3) is a potent STING agonist. diABZI-V/C-DBCO can release diABZI-amine upon activation by cathepsin B to activate STING, leading to the production of interferons and other immune-stimulatory molecules, thereby enhancing the immune system's response to tumors. The EC50 values for diABZI-V/C-DBCO and diABZI-amine in activating STING in THP1-Dual cells are 1.47 and 0.144 nM, respectively, and in primary mouse splenocytes, the EC50 values are 7.7 and 0.17 μM, respectively. diABZI-V/C-DBCO can be used in cancer immunotherapy research .
|
-
- HY-10964R
-
|
DMXAA (Standard); ASA-404 (Standard)
|
STING
IFNAR
Influenza Virus
|
Infection
Cancer
|
|
Vadimezan (Standard) (DMXAA (Standard)) is the analytical standard of Vadimezan (HY-10964). This product is intended for research and analytical applications. Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
|
-
- HY-155109
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
Antitumor agent-114 is a potent stimulator of interferon genes (STING) agonist. Antitumor agent-114 activates immunity and reduces tumor volume in a mouse model of breast cancer. Antitumor agent-114 can be used for immunity and cancer diseases research .
|
-
- HY-12326A
-
|
Cyclic diadenylate disodium; Cyclic-di-AMP disodium
|
STING
Bacterial
Endogenous Metabolite
|
Inflammation/Immunology
|
|
c-di-AMP (Cyclic diadenylate) sodium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP sodium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP sodium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .
|
-
- HY-176256
-
|
|
STING
|
Cancer
|
|
endo-S-cGAFMP (Compound 3) is a STING agonist. endo-S-cGAFMP induces the production of interferon regulatory factors and proinflammatory cytokines by activating the cGAS-STING pathway, thereby enhancing innate and adaptive immune responses. endo-S-cGAFMP has potent immunostimulatory capacity in THP1 monocytes and RAW macrophages (EC50 values of 2.45 μM and 5.54 μM, respectively). endo-S-cGAFMP has significant antitumor activity. endo-S-cGAFMP can be used as a potential cancer immunotherapeutic agent, especially for studies of systemic administration .
|
-
- HY-12326B
-
|
Cyclic diadenylate diammonium; Cyclic-di-AMP diammonium
|
STING
Bacterial
Endogenous Metabolite
|
Inflammation/Immunology
|
|
c-di-AMP diammonium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP diammonium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP diammonium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .
|
-
- HY-12326
-
|
Cyclic diadenylate; Cyclic-di-AMP
|
STING
Bacterial
Endogenous Metabolite
|
Inflammation/Immunology
|
|
c-di-AMP (Cyclic diadenylate) is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP (Cyclic diadenylate) is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP (Cyclic diadenylate) acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .
|
-
- HY-131454
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
SR-717 is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .
|
-
- HY-131454A
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
SR-717 free acid is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 free acid is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .
|
-
- HY-107780A
-
|
c-di-GMP sodium; cyclic diguanylate sodium; 5GP-5GP sodium
|
STING
Endogenous Metabolite
|
Cancer
|
|
Cyclic-di-GMP sodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP sodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP sodium can be used in cancer research .
|
-
- HY-107780
-
|
c-di-GMP; cyclic diguanylate; 5GP-5GP
|
STING
Endogenous Metabolite
|
Cancer
|
|
Cyclic-di-GMP is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research .
|
-
- HY-168384
-
|
|
STING
TNF Receptor
Interleukin Related
CD28
|
Inflammation/Immunology
|
|
M04 is an agonist of STING. It induces the expression of the IFN reporter gene in HEK293T cells expressing wild-type human STING, but does not induce this expression in HEK293T cells expressing the R71H-G230A-R293Q (HAQ) STING variant or in mouse RAW 264.7 cells, indicating that its activity is dependent on allelic and species variations. M04 induces the production of TNF-α, IL-10, IL-1β, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs). At a concentration of 50 µM, M04 stimulates dendritic cells isolated from PBMCs to express the MHC class II cell surface receptor HLA-DR and co-stimulatory molecules CD40, CD80, and CD86, and also enhances their ability to activate T cells in an ex vivo assay. M04 can be used in research on inflammatory immune diseases .
|
-
- HY-110382
-
|
c-di-GMP disodium; cyclic diguanylate disodium; 5GP-5GP disodium
|
STING
Endogenous Metabolite
|
Cancer
|
|
Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research .
|
-
- HY-107780B
-
|
c-di-GMP diammonium; cyclic diguanylate diammonium; 5GP-5GP diammonium
|
STING
Endogenous Metabolite
|
Cancer
|
|
Cyclic-di-GMP diammonium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP diammonium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP diammonium can be used in cancer research .
|
-
- HY-141662
-
|
|
STING
Drug-Linker Conjugates for ADC
|
Inflammation/Immunology
Cancer
|
|
2’,3’-cGAMP-C2-PPA is a cyclic dinucleotide interferon gene-stimulating protein (STING) agonist. 2’,3’-cGAMP-C2-PPA is a drug conjugated conjugate used to target antibody-drug conjugated conjugate (ADC) for the treatment of cancer. 2’,3’-cGAMP-C2-PPA can be used in the study of immune and tumor-related diseases .
|
-
- HY-172533
-
|
|
STING
|
Cancer
|
|
3’,5’-DiOA-dC is a hydrophobic nucleotide lipid and a ligand for the STING agonist c-di-GMP (CDG). 3’,5’-DiOA-dC can assemble with CDG and form stable cyclic dinucleotide nanoparticles via various supramolecular forces driven by molecular recognition. 3’,5’-DiOA-dC can decrease tumor weight and volume, increase CD8 T cell, neutrophils as well as NK cell counts in tumor microenvironment in combination with CDG. 3’,5’-DiOA-dC also increases the levels of TNF-α and IFN-γ in murine melanoma model .
|
-
- HY-B0984A
-
|
|
Calcium Channel
Ras
STING
Autophagy
|
Infection
Cardiovascular Disease
Cancer
|
|
Fendiline, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
|
-
- HY-B0984
-
|
|
Calcium Channel
Ras
STING
Autophagy
|
Infection
Cardiovascular Disease
Cancer
|
|
Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
|
-
- HY-B0984R
-
|
|
Calcium Channel
Ras
STING
Autophagy
|
Infection
Cardiovascular Disease
Cancer
|
|
Fendiline (hydrochloride) (Standard) is the analytical standard of Fendiline (hydrochloride). This product is intended for research and analytical applications. Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
|
-
- HY-110382S
-
|
13C20,15N10-c-di-GMP, 13C20,15N10-Cyclic diguaylate, 13C20,15N10-3’,5’-Cyclic diguaylic Acid
|
Isotope-Labeled Compounds
Endogenous Metabolite
STING
|
Cancer
|
|
13C20, 15N10-Cyclic di-GMP ( 13C20, 15N10-c-di-GMP) is 13C and 15N labeled Cyclic-di-GMP (disodium). Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research .
|
-
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-110382S
-
|
|
|
13C20, 15N10-Cyclic di-GMP ( 13C20, 15N10-c-di-GMP) is 13C and 15N labeled Cyclic-di-GMP (disodium). Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-162874
-
|
|
|
DBCO
|
|
diABZI-V/C-DBCO (Compound 3) is a potent STING agonist. diABZI-V/C-DBCO can release diABZI-amine upon activation by cathepsin B to activate STING, leading to the production of interferons and other immune-stimulatory molecules, thereby enhancing the immune system's response to tumors. The EC50 values for diABZI-V/C-DBCO and diABZI-amine in activating STING in THP1-Dual cells are 1.47 and 0.144 nM, respectively, and in primary mouse splenocytes, the EC50 values are 7.7 and 0.17 μM, respectively. diABZI-V/C-DBCO can be used in cancer immunotherapy research .
|
-
- HY-176126
-
|
|
|
Alkynes
|
|
STING agonist-42 (compound 8a) is a potent STING agonist. STING agonist-42 activates STING in THP1 and RAW 264.7 cells with EC50s of 0.06 and 14.15 μM, respectively .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![(S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide](http://file.medchemexpress.eu/product_pic/hy-174170.gif)
